

Supporting Information

Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis and Biological Evaluation

*Barbara Vergani, Giovanni Sandrone, Mattia Marchini, Chiara Ripamonti, Edoardo Cellupica, Elisabetta Galbiati, Gianluca Caprini, Gianfranco Pavich, Giulia Porro, Ilaria Rocchio, Maria Lattanzio, Marcello Pezzuto, Malgorzata Skorupska, Paola Cordella, Paolo Pagani, Pietro Pozzi, Roberta Pomarico, Daniela Modena, Flavio Leoni, Raffaella Perego, Gianluca Fossati, Christian Steinkühler and Andrea Stevenazzi**

Preclinical R&D, Italfarmaco Group, Via dei Lavoratori 54, I-20092 Cinisello Balsamo, Milan,
Italy

Table of Contents

<i>In vitro</i> determination of specific HDAC6 inhibitory activity (data related to Figure 8).....	S3
<i>In vivo</i> determination of specific HDAC6 inhibitory activity (data related to Figure 9).....	S4
Six-membered heteroaromatic central scaffold compounds.....	S5
Repeats of enzyme assay IC ₅₀ determination (for key compounds) and standard deviations.	S6
Repeats of cytotoxicity on PBMC and on 697 B-precursor acute lymphoblastic leukemia (B-Pre-ALL) cell line experiments (on key compounds) and standard deviations	S8
Homology model protocol	S11
Docking protocol	S11
Comparison between the best docking poses of compound 35 (Figure 7), Bavarostat and ACY-1083 into HDAC6 active site.....	S12
HPLC chromatograms of key compounds.....	S14

***In vitro* determination of specific HDAC6 inhibitory activity (data related to Figure 8)**

Table S1 - Tubulin and H3 acetylation in human 697 B-precursor acute lymphoblastic leukemia (B-Pre-ALL) cell line.

	α -tubulin ^a				H3 ^a		
	Conc (nM)				Conc (nM)		
compd	1000	333	111	37	1000	333	111
13	16±2	13±1	7±1	3±1	2±1	1±1	1±1
29	7±1	6±1	4±1	2±1	8±3	n.a.	n.a.
34	6±1	4±1	3±1	2±1	1±1	1±1	1±1
35	11±1	8±1	3±1	2±1	3±1	n.a.	n.a.
39	22±1	20±1	19±1	10±1	2±1	3±1	1±1
42	14±3	9±2	3±1	2±1	3±1	2±1	1±1
43	12±2	9±1	4±1	3±1	1±1	1±1	1±1
44	10±2	9±2	8±1	3±1	2±1	2±1	1±1
45	17±1	21±1	15±1	7±1	1±1	1±1	1±1
47	14±1	10±1	11±1	6±1	1±1	n.a.	n.a.
48	7 ±1	5±1	2±1	2±1	2±1	1±1	1±1
49	19±1	15±1	7±1	2±1	1±1	n.a.	n.a.
Givinostat	13±1	9±1	3±1	2±1	23±7	17±5	8±3

a. *fold increase* of the ratio of acetylated tubulin and total tubulin and of acetylated H3 and total H3 ratio towards control. The test has been carried out in dose/response (4-points for tubulin and 3-points for histone H3) starting from 1 μ M with 3-fold serial dilution (3 technical replicates).

n.a. not available.

***In vivo* determination of specific HDAC6 inhibitory activity (data related to Figure 9)**

Table S2 - Levels of tubulin and histone H3 acetylation and concentrations of compound **42** in the spleen and in plasma of mice following oral administration of the inhibitor (data presented in Figure 9A).

Time (hrs)	Ac-tubulin	Ac-H3	Compound 42 concentration	Compound 42 plasma concentration
	Fold increase (average \pm sem)		(ng/g spleen)	(ng/ml)
1	10.54 \pm 0.97	2.03 \pm 0.38	1357 \pm 492	958 \pm 362
4	1.68 \pm 0.21	0.83 \pm 0.07	106.1 \pm 26.6	17.8 \pm 3.3
24	0.84 \pm 0.02	0.72 \pm 0.05	17.1 \pm 2.6	0.7 \pm 0.4




Table S3 - Levels of tubulin and histone H3 acetylation and concentrations of compound **13** in the spleen and in plasma of mice following oral administration of the inhibitor (data presented in Figure 9B).

Time (hrs)	Ac-tubulin	Ac-H3	Compound 13 concentration	Compound 13 plasma concentration
	Fold increase (average \pm sem)		(ng/g spleen)	(ng/ml)
1	11.04 \pm 1.25	3.12 \pm 0.59	6140 \pm 1583	1989 \pm 638
4	1.94 \pm 0.21	1.14 \pm 0.04	109.2 \pm 24.1	16.0 \pm 4.8
24	0.80 \pm 0.04	0.85 \pm 0.05	17.5 \pm 3.3	1.3 \pm 0.1

Six-membered heteroaromatic central scaffold compounds

Some compounds bearing a six-membered heteroaromatic ring as a central scaffold were synthesized and tested. These compounds show quite low potency in HDAC6 inhibitory activity compared to compounds with five-membered heteroaromatic ring core, even if they retain a certain selectivity toward HDAC3.

Table S4 – Enzymatic activity of some Six-membered heteroaromatic central scaffold compounds

Compd code	Structure	HDAC6 IC ₅₀ (nM) ^a	HDAC3 IC ₅₀ (nM) ^a	Selectivity (HDAC3 IC ₅₀ /HDAC6 IC ₅₀)
ITF3858		621±16	5414±95	8.7
ITF3857		701±8	6691±154	9.5
ITF3743		129±2	1558±31	12.1

a - Enzymatic data (IC₅₀) in nM unit were obtained from curve-fitting of a 5-point enzymatic assay starting from 100, 30 or 10 µM with 10-fold serial dilution. Experiments were done in triplicate (single experiment). SDs were calculated on technical replicates.

Repeats of enzyme assay IC₅₀ determination (for key compounds) and standard deviations.

Table S5 – IC₅₀ calculation - Single experiments results

Enzyme	Compd	IC ₅₀ (nM)				Mean	Std Dev	repeats
HDAC6	13	9	8	8		8	1	3
	29	8	8	5		7	1	3
	33	8	7	7		7	1	3
	34	6	5	5		5	1	3
	35	3	5	2		3	2	3
	39	6	8	4		6	2	3
	42	27	15	15	9	17	8	4
	43	9	8	9		9	1	3
	44	4	4	1		3	2	3
	45	4	2	6		4	2	3
	46	5	4	6		5	1	3
	47	5	6	6		6	1	3
	48	6	9	15		10	4	3
	49	11	13	16		13	3	3
HDAC3	13	487	532	493		504	24	3
	29	974	1026	681	804	871	158	4
	33	6510	7831	6680	6357	6845	671	4
	34	5988	5243	4306		5179	843	3
	35	641	750	617		669	71	3
	39	2470	2803	2450		2574	198	3
	42	979	794	712	975	865	134	4

	43	2827	2074	1871	1606	2095	524	4
	44	2635	2273	2348		2419	191	3
	45	1776	1870	1885	1584	1779	138	4
	46	2608	2729	1887		2408	455	3
	47	3005	2661	2669		2778	196	3
	48	2936	3635	3741	3851	3541	413	4
	49	13717	10953	10382	8614	10917	2116	4
HDAC1	13	1015	1004			1010	8	2
	29	812	1047			929	166	2
	33	7512	6768			7140	526	2
	34	4447	3472			3960	689	2
	35	1425	700			1063	513	2
	39	2898	2436			2667	327	2
	42	1094	953	829	820	924	129	4
	43	3991	4288			4140	210	2
	44	2517	2107			2312	290	2
	45	2878	2983			2931	74	2
	46	3659	4677			4168	720	2
	47	3182	3452			3317	191	2
	48	5162	5269			5216	76	2
	49	7377	8838			8107	1033	2

Repeats of cytotoxicity on PBMC and on 697 B-precursor acute lymphoblastic leukemia (B-Pre-ALL) cell line experiments (on key compounds) and standard deviations

Table S6 – Cytotoxicity on PBMC

Compd	PBMC cytotoxicity (nM)	Standard deviation	repeats
13	5857	4230	6
29	4274	3507	6
33	>10000	-	2
34	7387	7608	4
35	5524	6334	2
39	>10000	-	2
42	5387	5128	5
43	>10000	-	3
44	>10000	-	3
45	>10000	-	1
46	>10000	-	3
47	5987	3892	3
48	7445	6210	3
49	3963	4108	5
Givinostat	313		

Table S7 – Cytotoxicity on 697 B-precursor acute lymphoblastic leukemia (B-Pre-ALL) cell line

Compd	697 cell line cytotoxicity (nM)	Standard deviations	repeats
13	>10000	-	3
29	3634	2271	6
33	>10000	-	5
34	>10000	-	7
35	6489	2603	6
39	>10000	-	3
42	8934	5531	6
43	5506	3031	4
44	2749	1865	7
45	>10000	-	6
46	5983	2844	5
47	>10000	-	5
48	>10000	-	4
49	>10000	-	3
Givinostat	100		

Both cytotoxicity test on 697 (B-Pre-AL) and hPBMC were performed in a concentration range between 10 and 10000 nM (Higher concentrations lead to phenomena which could compromise the assay, such as inhibitor precipitation). The IC₅₀ of the majority of tested compounds could not be determined, being higher than 10000 nM. The high standard deviations of the other compounds

are due to the closeness of the IC₅₀ value to the experiment highest dose. These data state that all the tested compounds are not cytotoxic.

Cell cytotoxicity assay. Cytotoxic activities of the compounds were evaluated in the human 697 promyelocytic B leukemia cell line (ACC 42, DSMZ- Deutsche Sammlung von Mikroorganismen und Zellkulturen) and on human peripheral blood mononuclear cells (PBMCs) using a commercial viability assay which measures the mitochondrial activity. 697 cells were plated at 2×10^4 cells per well, and the compounds were added in concentrations ranging from 10 to 10000 nM. After 48 h of incubation, cell viability was evaluated with CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's instructions.

hPBMC from healthy donors were separated by density gradient on Ficoll Hypaque.

PBMCs were plated at 5×10^5 cell per well and compounds were added in a concentration range from 10 to 10000 nM. After 72 h of incubation, cell viability was evaluated as described before.

Homology model protocol

The homology model h-HDAC6-CD2.pdb was prepared using "Build Homology Model" protocols available in Discovery Studio, and based on MODELER (Sali, A.; Blundell, T.L., *J. Mol. Biol.* **1993**, 234(3), 779-815.). Parameters are set to the default values suggested by supplier.

Sequences of templates (h-HDAC8: PDB code 1T64, h-HDAC2: PDB code 4LXZ and h-HDAC3: PDB code 4A69) and the portion of h-HDAC6 target of homology modeling (h-HDAC6-CD2, residues from 485 to 835, GenBank: AAH69243.1 - Ref. Strausberg et al., *Proc. Natl. Acad. Sci.* **2002**, 99, 16899-16903). Water molecules available in templates were removed, whereas all ligands coprecipitated with template were conserved and transferred to the model. Optimization level was set to the highest level.

Docking protocol

Docking calculation were performed using libdoc protocol of Discovery Studio (DS) Suite, focusing the conformational search of candidates in a sphere centered in the center of mass of aligned inhibitors and having radius equal to 8.0 Å. The volume includes both L1 and L2 loops, the catalytic core, the zinc cation and its residue directly bound to the metal ion.

The best score function for poses ranking was detected in the preliminary calculation, where a training set of HDAC6 selective and pan inhibitors are mixed with compounds exhibiting low isoform 6 potency (at least 10-fold).

Final Receiving Operator Curves (ROC) were based on the Dreiding scores, which exhibited the highest number of true positive hits, on the basis of the top scoring function value.

Comparison between the best docking poses of compound 35 (related to Figure 7), Bavarostat and ACY-1083 into HDAC6 active site.




Figure S1.1 (related to Figure 7). Compound 35 h-CD-HDAC6 complex: conformer detected in the docking experiment. Protein PDB code: 5EDU




Figure S1.2. Bavarostat h-CD-HDAC6 virtual complex: the “binding” conformer was extracted from Bavarostat-z-CD2-HDAC6 complex (PDB code 6DVO), preliminary superimposed to h-CD2-HDAC6 (PDB code 5EDU) by using sequences alignment.






Figure S1.3. ACY-1083 h-CD-HDAC6 virtual complex: the “binding” conformer was extracted from ACY-1083-z-CD2-HDAC6 complex (PDB code 5WGM), preliminary superimposed to h-CD2-HDAC6 (PDB code 5EDU) by using sequences alignment.

HPLC chromatograms of key compounds

Compound 13



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.200	MM	0.3737	31.56440	1.40759	0.5851
2	16.307	MF	0.1412	5245.92725	619.26727	97.2488
3	17.618	FM	0.8307	60.70369	1.21788	1.1253
4	19.965	MM	0.1715	28.37240	2.75685	0.5260
5	24.357	MM	0.3163	27.76843	1.46313	0.5148

Totals : 5394.33616 626.11272

Compound 29



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.820	MF	0.1079	1.03077e4	1592.32324	96.1647
2	13.439	FM	0.3375	136.16881	6.72462	1.2704
3	14.663	MM	0.1033	21.78426	3.51447	0.2032
4	17.013	MM	0.1082	253.14133	38.99165	2.3617

Totals : 1.07188e4 1641.55398

*** End of Report ***

Compound 33



AREA PERCENT REPORT


Sorted By : Retention Time
Multiplier : 1.000000
Dilution : 1.000000
Use Multiplier & Dilution Factor with ISTDs

Signal 1 : MWD1 D, Sig=230,16 Ref=off

Peak #	RetTime [min]	Type	Area [mAU*s]	Width [s]	Height [mAU]	Area %
1	7.513	BV	438.4840	0.074	91.381	1.873
2	8.460	BB	29.0845	0.069	6.349	0.124
3	14.328	BV	2.2477e4	0.121	2950.154	96.020
4	14.786	VV	147.0223	0.123	16.631	0.628
5	15.727	BB	43.1524	0.094	6.988	0.184
6	18.576	BB	100.9549	0.108	14.001	0.431
7	23.995	BB	88.4048	0.134	9.752	0.378
8	24.460	BB	84.4804	0.115	11.134	0.361

Totals : 23408.943 3106.390



*** End of Report ***

O=C(O)C1=CC=C(C=C1C2=NN=C3C(=N2)C4=CC=CC=N4)C5=CC=C(C=C5)F

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

S17

Compound 35



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.055	MM	0.1364	1.23599e4	1510.09155	99.0300
2	15.292	BB	0.1167	48.12162	6.18687	0.3856
3	16.128	BB	0.1035	23.01808	3.37705	0.1844
4	16.654	BB	0.0960	25.01641	4.05269	0.2004
5	18.139	MM	0.1979	16.77694	1.41315	0.1344
6	19.901	BB	0.1106	8.12793	1.12135	0.0651

Totals : 1.24810e4 1526.24267

Compound 39



AREA PERCENT REPORT

Sorted By : Retention Time
Multiplier : 1.000000
Dilution : 1.000000
Use Multiplier & Dilution Factor with ISTDs



Signal 1 : MWD1 D, Sig=230,16 Ref=off

Peak #	RetTime [min]	Type	Area [mAU*s]	Width [s]	Height [mAU]	Area %
1	12.157	BV	75.4362	0.058	19.781	0.501
2	12.226	VB	117.5889	0.073	23.137	0.781
3	13.102	BV	1.4711e4	0.085	2660.644	97.740
4	15.761	VB	147.1682	0.096	23.239	0.978

Totals : 15051.009 2726.801

*** End of Report ***

Compound 42



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.633	MF	0.1217	4746.85742	650.32465	98.5949
2	17.916	FM	0.1213	10.75318	1.47803	0.2233
3	19.761	MM	0.1569	4.95489	5.26211e-1	0.1029
4	20.345	MM	0.1245	6.26612	8.39117e-1	0.1302
5	21.683	MM	0.1185	41.23109	5.79919	0.8564
6	23.520	MM	0.1883	4.44433	3.93408e-1	0.0923

Totals : 4814.50704 659.36060

Compound 43



AREA PERCENT REPORT

Sorted By : Retention Time
Multiplier : 1.000000
Dilution : 1.000000
Use Multiplier & Dilution Factor with ISTDs



Signal 1 : MWD1 D, Sig=230,16 Ref=off

Peak #	RetTime [min]	Type	Area [mAU*s]	Width [s]	Height [mAU]	Area %
1	12.765	VV	142.2237	0.062	34.635	0.996
2	12.847	VB	243.4736	0.080	44.129	1.705
3	13.713	VV	1.3720e4	0.086	2442.290	96.064
4	16.632	BV	27.0258	0.071	5.910	0.189
5	16.749	VB	149.4247	0.104	20.842	1.046

Totals : 14282.465 2547.806

*** End of Report ***

Compound 44



AREA PERCENT REPORT

Sorted By : Retention Time
Multiplier : 1.000000
Dilution : 1.000000
Use Multiplier & Dilution Factor with ISTDs



Signal 1 : MWD1 A, Sig=220,8 Ref=off

Peak #	RetTime [min]	Type	Area [mAU*s]	Width [s]	Height [mAU]	Area %
1	15.439	BV	2.0405e4	0.112	2847.222	98.966
2	17.019	VB	77.4276	0.119	9.334	0.376
3	19.905	BB	135.7432	0.112	18.491	0.658

Totals : 20617.825 2875.048

*** End of Report ***

Compound 45



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs



Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.501	BB	0.0938	6.83267	1.11008	0.1669
2	11.312	BB	0.0938	21.14806	3.43508	0.5167
3	12.128	MM	0.1059	4047.27197	636.98608	98.8851
4	15.857	BB	0.0956	17.65212	2.87751	0.4313

Totals : 4092.90483 644.40875

*** End of Report ***

Compound 46



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.246	MM	0.1214	9.85570	1.35345	0.1667
2	14.441	MM	0.1169	25.81969	3.68123	0.4368
3	15.276	MF	0.1139	5670.03955	829.62567	95.9245
4	15.768	FM	0.1392	16.73606	2.00368	0.2831
5	15.958	FM	0.1398	37.98315	4.52803	0.6426
6	16.321	FM	0.1110	10.75467	1.61549	0.1819
7	17.031	MM	0.1052	20.17744	3.19765	0.3414
8	17.849	MM	0.1235	111.34515	15.02161	1.8837
9	20.837	MM	0.2144	8.22828	4.97986e-1	0.1392

Totals : 5910.93969 861.52480

Compound 47



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.632	BB	0.1059	8536.11914	1246.60913	98.5507
2	17.607	BB	0.0962	73.10281	11.81493	0.8440
3	19.982	BV	0.1227	19.25979	2.32263	0.2224
4	20.140	VB	0.0995	10.28613	1.54806	0.1188
5	24.964	BB	0.1070	22.88335	3.29540	0.2642

Totals : 8661.65123 1265.59016

Compound 48



Area Percent Report



Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.552	MM	0.2451	9.51850	6.47343e-1	0.2182
2	16.917	MF	0.1075	4251.33350	658.83563	97.4705
3	17.427	FM	0.1160	73.89431	10.61377	1.6942
4	18.291	MM	0.1224	6.55358	8.92673e-1	0.1503
5	19.495	MM	0.1005	14.08372	2.33581	0.3229
6	22.248	MM	0.1673	6.27865	6.25553e-1	0.1440

Totals : 4361.66227 673.95077

Compound 49



Area Percent Report

Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs

Signal 1: DAD1 A, Sig=230,4 Ref=550,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.581	MM	0.1920	10.10718	8.77479e-1	0.1360
2	14.009	BV	0.1380	23.20093	2.76172	0.3121
3	14.404	MF	0.1244	41.32228	5.53506	0.5558
4	14.705	FM	0.1201	7243.45898	1005.46704	97.4330
5	15.666	FM	0.3124	15.14232	8.07779e-1	0.2037
6	17.934	BB	0.0991	101.06865	15.70725	1.3595

Totals : 7434.30035 1031.15633